By Hugo Francisco de Souza Reviewed by Susha Cheriyedath, M.Sc. May 31 2026 A major analysis shows that more drug exposure does not always mean better disease control, as high-dose ocrelizumab cleared more circulating B cells without improving disability outcomes in MS. Efficacy and safety of a bodyweight–adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials .